Cutaneous adverse reactions to lenalidomide.

Area of Science:

• Pharmacology
• Dermatology
• Oncology

Background:

• Lenalidomide is a key immunomodulatory drug (IMiD) for treating multiple myeloma (MM), myelodysplastic syndromes (MS), and amyloidosis.
• While effective, lenalidomide is associated with a range of adverse reactions, including myelosuppression, thromboembolism, and secondary malignancies.
• Cutaneous adverse reactions are a significant, though often under-discussed, aspect of lenalidomide therapy.

Purpose of the Study:

• To comprehensively review and consolidate information on the cutaneous adverse reactions associated with lenalidomide use.
• To highlight the spectrum of skin-related side effects observed in patients treated with lenalidomide.
• To provide a resource for clinicians managing patients on lenalidomide therapy.

Main Methods:

• Systematic literature search for studies reporting cutaneous adverse events linked to lenalidomide.
• Analysis of reported dermatological side effects, including their incidence, clinical presentation, and management strategies.
• Synthesis of findings to categorize and describe the various skin reactions.

Main Results:

• Common cutaneous reactions include rash, pruritus, and dry skin.
• Less frequent but serious reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis have been reported.
• Management often involves topical or systemic corticosteroids, dose modification, or discontinuation of lenalidomide.

Conclusions:

• Cutaneous adverse reactions are a frequent and important consideration in lenalidomide therapy.
• Early recognition and appropriate management of skin reactions are crucial for patient compliance and treatment success.
• Further research into the mechanisms and prevention of lenalidomide-induced dermatological toxicity is warranted.